BridgeMD
12-month study of probiotic effects in non-infectious uveitis treatment
EU CTIS ID: 2024-517946-32-00
What this study is testing
To evaluate the efficacy of Escherichia coli Nissle 1917 (ECN) in patients with autoimmune uveitis
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Principal inclusion criteria: Adults ≥ 18 and < 65 years of age with autoimmune anterior, intermediate, posterior or pan-uveitis, who experienced flare-up of uveitis within 6 months prior to baseline visit
You likely can't join if
- Principal exclusion criteria: Uveitis of infectious etiology, active uveitis requiring an increase in systemic therapy or initiation of biological treatment, etc. (See study protocol for full list)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.